Ignite Creation Date:
2024-05-06 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 12:49 PM
Study NCT ID:
NCT03580668
Status:
COMPLETED
Last Update Posted:
2024-06-18
First Post:
2018-06-26
Brief Title:
Effectiveness Safety Adherence and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir EmtricitabineTenofovir Alafenamide
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
Multi-center Canadian Non-interventional Cohort Study of the Effectiveness Safety Adherence and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir EmtricitabineTenofovir Alafenamide BFTAF
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BIC-STaR
Brief Summary:
The primary objective of this study is to evaluate HIV-1 RNA suppression defined as HIV-1 RNA 50 copiesmL at 12 months after initiating or switching to Bictegravir EmtricitabineTenofovir alafenamide BFTAF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None